Endocytic mechanisms are crucial for targeted drug delivery, enabling precise localization of therapeutics to subcellular organelles. This review discusses the role of endocytosis in drug delivery, focusing on receptor-mediated endocytosis (RME) and its applications in treating diseases such as lysosomal storage diseases (LSDs), Alzheimer's disease, and cancer. RME allows for the internalization of macromolecules through high-affinity ligand-receptor interactions, leading to targeted delivery to endosomes and lysosomes. This process is essential for delivering enzymes and drugs to specific cellular compartments, enhancing therapeutic efficacy. Endocytosis involves various mechanisms, including clathrin-dependent and clathrin-independent pathways. Clathrin-dependent RME is well-characterized and involves the formation of coated pits, leading to the internalization of macromolecules and their subsequent trafficking to lysosomes. In contrast, clathrin-independent endocytosis, such as caveolae-mediated endocytosis, allows for less destructive delivery to non-lysosomal compartments. These mechanisms are vital for delivering therapeutics to specific organelles, particularly in diseases where lysosomal dysfunction is a key factor. Targeting drug delivery to endosomes and lysosomes offers several advantages, including the ability to exploit upregulated membrane receptors in diseased tissues and to control the intracellular fate of therapeutics. For example, in LSDs, targeted delivery of enzymes to lysosomes can correct enzyme deficiencies. Similarly, in cancer, targeted delivery can enhance drug accumulation in tumor cells while minimizing toxicity to healthy tissues. Current research focuses on developing synthetic receptors and nanoscale carriers for high-affinity targeting, improving the efficiency and specificity of drug delivery. These advancements highlight the importance of understanding endocytic mechanisms in the development of effective therapeutic strategies for a wide range of diseases.Endocytic mechanisms are crucial for targeted drug delivery, enabling precise localization of therapeutics to subcellular organelles. This review discusses the role of endocytosis in drug delivery, focusing on receptor-mediated endocytosis (RME) and its applications in treating diseases such as lysosomal storage diseases (LSDs), Alzheimer's disease, and cancer. RME allows for the internalization of macromolecules through high-affinity ligand-receptor interactions, leading to targeted delivery to endosomes and lysosomes. This process is essential for delivering enzymes and drugs to specific cellular compartments, enhancing therapeutic efficacy. Endocytosis involves various mechanisms, including clathrin-dependent and clathrin-independent pathways. Clathrin-dependent RME is well-characterized and involves the formation of coated pits, leading to the internalization of macromolecules and their subsequent trafficking to lysosomes. In contrast, clathrin-independent endocytosis, such as caveolae-mediated endocytosis, allows for less destructive delivery to non-lysosomal compartments. These mechanisms are vital for delivering therapeutics to specific organelles, particularly in diseases where lysosomal dysfunction is a key factor. Targeting drug delivery to endosomes and lysosomes offers several advantages, including the ability to exploit upregulated membrane receptors in diseased tissues and to control the intracellular fate of therapeutics. For example, in LSDs, targeted delivery of enzymes to lysosomes can correct enzyme deficiencies. Similarly, in cancer, targeted delivery can enhance drug accumulation in tumor cells while minimizing toxicity to healthy tissues. Current research focuses on developing synthetic receptors and nanoscale carriers for high-affinity targeting, improving the efficiency and specificity of drug delivery. These advancements highlight the importance of understanding endocytic mechanisms in the development of effective therapeutic strategies for a wide range of diseases.